Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavunalimab - Xencor

Next Previous
Drug Profile

Bavunalimab - Xencor

Alternative Names: Anti-CTLA-4/anti-LAG-3 bispecific monoclonal antibody - Xencor; CTLA-4 x LAG-3 - Xencor; CTLA-4xLAG-3 bispecific antibody - Xencor; Pavunalimab; XmAb-22841; XmAb-841

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 16 Feb 2023 Xencor and ICON complete the phase I DUET-4 trial in Solid tumours (Monotherapy, Combination therapy, Late stage disease, Second-line therapy or greater) in USA (IV) (NCT03849469)
  • 25 Jan 2023 University of California plans a phase Ib/II trial for Malignant melanoma (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IV) in April 2023 (NCT05695898)
  • 31 Dec 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top